

John Laterra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3824191/publications.pdf>

Version: 2024-02-01

122
papers

8,035
citations

47006

47
h-index

51608

86
g-index

122
all docs

122
docs citations

122
times ranked

9877
citing authors

#	ARTICLE	IF	CITATIONS
1	Review and consensus recommendations on clinical ^{3T} weighted imaging approaches at ^{3T}: Application to brain tumors. Magnetic Resonance in Medicine, 2022, 88, 546-574.	3.0	79
2	Abstract PR013: Oct4 and Sox2 induce cellular transition of glioma stem cells to an immune suppressive, regulatory T cell-like state. Cancer Research, 2022, 82, PR013-PR013.	0.9	0
3	Reprogramming Transcription Factors Oct4 and Sox2 Induce a BRD-Dependent Immunosuppressive Transcriptome in GBM-Propagating Cells. Cancer Research, 2021, 81, 2457-2469.	0.9	31
4	EGFR Activates a TAZ-Driven Oncogenic Program in Glioblastoma. Cancer Research, 2021, 81, 3580-3592.	0.9	12
5	Opinion: miRNAs â€œ The new wave of molecular cancer therapeutics. Translational Oncology, 2021, 14, 101064.	3.7	3
6	Abstract 2419: Two-tiered inhibition of TGFBR2 signaling via ITD-1 and miR-149-3p targets CD44High glioma stem cells and non-stem-like GBM cells. , 2021, , .		0
7	Monoallelic IDH1 R132H Mutation Mediates Glioma Cell Response to Anticancer Therapies via Induction of Senescence. Molecular Cancer Research, 2021, 19, 1878-1888.	3.4	2
8	Mutant IDH1 promotes phagocytic function of microglia/macrophages in gliomas by downregulating ICAM1. Cancer Letters, 2021, 517, 35-45.	7.2	15
9	STEM-03. Oct4/Sox2 DRIVE AN IMMUNOSUPPRESSIVE GSC PHENOTYPE BY INDUCING T-REG EFFECTOR GENES VIA TGFBR2 SIGNALING. Neuro-Oncology, 2021, 23, vi21-vi22.	1.2	1
10	EXTH-16. LP-184, A NOVEL ALKYLATING AGENT, IS EFFECTIVE IN GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi166-vi167.	1.2	0
11	^d glucose weighted chemical exchange saturation transfer (glucoCEST) based dynamic glucose enhanced (DGE) MRI at 3T: early experience in healthy volunteers and brain tumor patients. Magnetic Resonance in Medicine, 2020, 84, 247-262.	3.0	41
12	Hemophagocytic Lymphohistiocytosis Secondary to PD-1 and IDO Inhibition in a Patient with Refractory Glioblastoma. Case Reports in Oncology, 2020, 13, 508-514.	0.7	15
13	A Sox2:miR-486-5p Axis Regulates Survival of GBM Cells by Inhibiting Tumor Suppressor Networks. Cancer Research, 2020, 80, 1644-1655.	0.9	34
14	ShRNA-based POLD2 expression knockdown sensitizes glioblastoma to DNA-Damaging therapeutics. Cancer Letters, 2020, 482, 126-135.	7.2	9
15	Prospective acceleration of parallel RF transmission based 3D chemical exchange saturation transfer imaging with compressed sensing. Magnetic Resonance in Medicine, 2019, 82, 1812-1821.	3.0	25
16	Extracellular Matrix Protein Tenascin C Increases Phagocytosis Mediated by CD47 Loss of Function in Glioblastoma. Cancer Research, 2019, 79, 2697-2708.	0.9	48
17	The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma. Magnetic Resonance in Medicine, 2019, 81, 3798-3807.	3.0	13
18	CEST MRI of 3â€œmethylâ€œ glucose uptake and accumulation in brain tumors. Magnetic Resonance in Medicine, 2019, 81, 1993-2000.	3.0	42

#	ARTICLE	IF	CITATIONS
19	Identifying Recurrent Malignant Glioma after Treatment Using Amide Proton Transfer-Weighted MR Imaging: A Validation Study with Image-Guided Stereotactic Biopsy. <i>Clinical Cancer Research</i> , 2019, 25, 552-561.	7.0	104
20	Synthetic mRNAs Drive Highly Efficient iPS Cell Differentiation to Dopaminergic Neurons. <i>Stem Cells Translational Medicine</i> , 2019, 8, 112-123.	3.3	39
21	Targeting UDP-glucose 6-dehydrogenase inhibits glioblastoma growth and migration. <i>Oncogene</i> , 2018, 37, 2615-2629.	5.9	37
22	Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells. <i>BMC Cancer</i> , 2018, 18, 1025.	2.6	14
23	Bioreducible Polymeric Nanoparticles Containing Multiplexed Cancer Stem Cell Regulating miRNAs Inhibit Glioblastoma Growth and Prolong Survival. <i>Nano Letters</i> , 2018, 18, 4086-4094.	9.1	117
24	Neuro-Oncology: Current Concepts and Emerging Therapeutics. <i>Neurotherapeutics</i> , 2017, 14, 253-255.	4.4	1
25	TET1 deficiency attenuates the DNA damage response and promotes resistance to DNA damaging agents. <i>Epigenetics</i> , 2017, 12, 854-864.	2.7	20
26	Amide proton transfer-weighted magnetic resonance image-guided stereotactic biopsy in patients with newly diagnosed gliomas. <i>European Journal of Cancer</i> , 2017, 83, 9-18.	2.8	82
27	Language Mapping Using T2-Prepared BOLD Functional MRI in the Presence of Large Susceptibility Artifacts—Initial Results in Patients With Brain Tumor and Epilepsy. <i>Tomography</i> , 2017, 3, 105-113.	1.8	9
28	Investigational new drugs for brain cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 937-956.	4.1	16
29	Regulation of Glioblastoma Tumor-Propagating Cells by the Integrin Partner Tetraspanin CD151. <i>Neoplasia</i> , 2016, 18, 185-198.	5.3	22
30	Microarray-Based Phospho-Proteomic Profiling of Complex Biological Systems. <i>Translational Oncology</i> , 2016, 9, 124-129.	3.7	6
31	A monoclonal antibody against KCNK9 K ⁺ channel extracellular domain inhibits tumour growth and metastasis. <i>Nature Communications</i> , 2016, 7, 10339.	12.8	57
32	Salicylic Acid Conjugated Dendrimers Are a Tunable, High Performance CEST MRI NanoPlatform. <i>Nano Letters</i> , 2016, 16, 2248-2253.	9.1	43
33	Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation. <i>Neuro-Oncology</i> , 2016, 18, 507-517.	1.2	102
34	Multiecho Length and Offset VARied Saturation (MeLOVARS) method for improved CEST imaging. <i>Magnetic Resonance in Medicine</i> , 2015, 73, 488-496.	3.0	27
35	Dynamic glucose enhanced (DGE) MRI for combined imaging of blood-brain barrier break down and increased blood volume in brain cancer. <i>Magnetic Resonance in Medicine</i> , 2015, 74, 1556-1563.	3.0	94
36	Cancer Stem Cells: Dynamic Entities in an Ever-Evolving Paradigm. <i>Biology and Medicine (Aligarh)</i> , 2015, s2, .	0.3	10

#	ARTICLE	IF	CITATIONS
37	Dynamic Glucose-Enhanced (DGE) MRI: Translation to Human Scanning and First Results in Glioma Patients. <i>Tomography</i> , 2015, 1, 105-114.	1.8	153
38	The cancer stem cell phenotype: You can't win until you learn how to lose it. <i>Molecular and Cellular Oncology</i> , 2015, 2, e989760.	0.7	3
39	Kruppel-like Factor-9 (KLF9) Inhibits Glioblastoma Stemness through Global Transcription Repression and Integrin $\beta 6$ Inhibition. <i>Journal of Biological Chemistry</i> , 2014, 289, 32742-32756.	3.4	67
40	Proneural Transcription Factor Atoh1 Drives Highly Efficient Differentiation of Human Pluripotent Stem Cells Into Dopaminergic Neurons. <i>Stem Cells Translational Medicine</i> , 2014, 3, 888-898.	3.3	35
41	HMMR Maintains the Stemness and Tumorigenicity of Glioblastoma Stem-like Cells. <i>Cancer Research</i> , 2014, 74, 3168-3179.	0.9	101
42	Quantitative multiparametric MRI assessment of glioma response to radiotherapy in a rat model. <i>Neuro-Oncology</i> , 2014, 16, 856-867.	1.2	45
43	In Vivo c-Met Pathway Inhibition Depletes Human Glioma Xenografts of Tumor-Propagating Stem-Like Cells. <i>Translational Oncology</i> , 2013, 6, 104-IN1.	3.7	44
44	Three-dimensional amide proton transfer MR imaging of gliomas: Initial experience and comparison with gadolinium enhancement. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 38, 1119-1128.	3.4	181
45	Profiling the Dynamics of a Human Phosphorylome Reveals New Components in HGF/c-Met Signaling. <i>PLoS ONE</i> , 2013, 8, e72671.	2.5	19
46	Collagen IV and CXC chemokine-derived antiangiogenic peptides suppress glioma xenograft growth. <i>Anti-Cancer Drugs</i> , 2012, 23, 706-712.	1.4	16
47	Cancer Stem Cells: Distinct Entities or Dynamically Regulated Phenotypes?. <i>Cancer Research</i> , 2012, 72, 576-580.	0.9	197
48	Regulation of glioblastoma multiforme stem-like cells by inhibitor of DNA binding proteins and oligodendroglial lineage-associated transcription factors. <i>Cancer Science</i> , 2012, 103, 1028-1037.	3.9	20
49	Evaluation of radiation necrosis and malignant glioma in rat models using diffusion tensor MR imaging. <i>Journal of Neuro-Oncology</i> , 2012, 107, 51-60.	2.9	24
50	Lipid metabolism alterations in U87 glioma cells deficient in very long-chain acyl-CoA synthetase 3 are associated with a less malignant phenotype. <i>FASEB Journal</i> , 2012, 26, 996.1.	0.5	0
51	Importance of Very Long Chain Acyl-CoA Synthetase 3 (ACSVL3) in cholesterol homeostasis and lipid raft signaling in U87 glioma cells. <i>FASEB Journal</i> , 2012, 26, .	0.5	0
52	PTEN reconstitution alters glioma responses to c-Met pathway inhibition. <i>Anti-Cancer Drugs</i> , 2011, 22, 905-912.	1.4	12
53	Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides. <i>Nature Medicine</i> , 2011, 17, 130-134.	30.7	448
54	Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression. <i>Nature Medicine</i> , 2011, 17, 123-129.	30.7	84

#	ARTICLE	IF	CITATIONS
55	KrÄppel-Like Family of Transcription Factor 9, a Differentiation-Associated Transcription Factor, Suppresses Notch1 Signaling and Inhibits Glioblastoma-Initiating Stem Cells. <i>Stem Cells</i> , 2011, 29, 20-31.	3.2	80
56	c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 9951-9956.	7.1	232
57	A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2011, 13, 437-446.	1.2	153
58	FasL gene knock-down therapy enhances the anti-glioma immune response. <i>Neuro-Oncology</i> , 2010, 12, 482-9.	1.2	19
59	Cyr61 Mediates Hepatocyte Growth Factor-Dependent Tumor Cell Growth, Migration, and Akt Activation. <i>Cancer Research</i> , 2010, 70, 2932-2941.	0.9	47
60	Molecular Therapy Targeting Sonic Hedgehog and Hepatocyte Growth Factor Signaling in a Mouse Model of Medulloblastoma. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2627-2636.	4.1	35
61	Prognostic significance of contrast-enhancing anaplastic astrocytomas in adults. <i>Journal of Neurosurgery</i> , 2010, 113, 286-292.	1.6	37
62	Unmasking the multiforme in glioblastoma. <i>Nature Reviews Neurology</i> , 2010, 6, 304-305.	10.1	10
63	Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. <i>Journal of Neurosurgery</i> , 2010, 112, 10-17.	1.6	173
64	Identification of Inhibitors of ABCG2 by a Bioluminescence Imaging-Based High-Throughput Assay. <i>Cancer Research</i> , 2009, 69, 5867-5875.	0.9	44
65	EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1751-1760.	4.1	61
66	Acyl-CoA Synthetase VL3 Knockdown Inhibits Human Glioma Cell Proliferation and Tumorigenicity. <i>Cancer Research</i> , 2009, 69, 9175-9182.	0.9	42
67	Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. <i>Journal of Neurosurgery</i> , 2009, 110, 583-588.	1.6	252
68	<i>DNER</i> , an Epigenetically Modulated Gene, Regulates Glioblastoma-Derived Neurosphere Cell Differentiation and Tumor Propagation. <i>Stem Cells</i> , 2009, 27, 1473-1486.	3.2	84
69	Epilepsy and temporal lobe injury after skull base proton beam therapy. <i>Journal of Clinical Neuroscience</i> , 2009, 16, 1220-1221.	1.5	2
70	Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449. <i>New England Journal of Medicine</i> , 2009, 361, 1173-1178.	27.0	951
71	Hedgehog Pathway Inhibitor HhAntag691 Is a Potent Inhibitor of ABCG2/BCRP and ABCB1/Pgp. <i>Neoplasia</i> , 2009, 11, 96-101.	5.3	71
72	Camptothecin and Fas receptor agonists synergistically induce medulloblastoma cell death: ROS-dependent mechanisms. <i>Anti-Cancer Drugs</i> , 2009, 20, 770-778.	1.4	19

#	ARTICLE	IF	CITATIONS
73	Amide proton transfer imaging of 9L gliosarcoma and human glioblastoma xenografts. <i>NMR in Biomedicine</i> , 2008, 21, 489-497.	2.8	92
74	Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma. <i>Laboratory Investigation</i> , 2008, 88, 98-111.	3.7	61
75	Abnormal DNA Methylation of <i>CD133</i> in Colorectal and Glioblastoma Tumors. <i>Cancer Research</i> , 2008, 68, 8094-8103.	0.9	153
76	PTEN Has Tumor-Promoting Properties in the Setting of Gain-of-Function p53 Mutations. <i>Cancer Research</i> , 2008, 68, 1723-1731.	0.9	92
77	Hepatocyte Growth Factor and Sonic Hedgehog Expression in Cerebellar Neural Progenitor Cells Costimulate Medulloblastoma Initiation and Growth. <i>Cancer Research</i> , 2008, 68, 7838-7845.	0.9	42
78	Transcription-Dependent Epidermal Growth Factor Receptor Activation by Hepatocyte Growth Factor. <i>Molecular Cancer Research</i> , 2008, 6, 139-150.	3.4	85
79	ABCG2/BCRP Expression Modulates <i>scp</i> -Luciferin-Based Bioluminescence Imaging. <i>Cancer Research</i> , 2007, 67, 9389-9397.	0.9	80
80	Ribotoxic Stress Sensitizes Glioblastoma Cells to Death Receptor-Induced Apoptosis: Requirements for c-Jun NH2-Terminal Kinase and Bim. <i>Molecular Cancer Research</i> , 2007, 5, 783-792.	3.4	40
81	Emerging monoclonal antibody therapies for malignant gliomas. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 477-494.	4.1	13
82	Hepatocyte growth factor increases mitochondrial mass in glioblastoma cells. <i>Biochemical and Biophysical Research Communications</i> , 2006, 345, 1358-1364.	2.1	6
83	Transgenic expression of human FGF-1 protects against hypoxic-ischemic injury in perinatal brain by intervening at caspase-XIAP signaling cascades. <i>Neurobiology of Disease</i> , 2006, 22, 677-690.	4.4	27
84	Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. <i>Clinical Cancer Research</i> , 2006, 12, 1292-1298.	7.0	153
85	Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis. <i>Laboratory Investigation</i> , 2005, 85, 1457-1470.	3.7	102
86	Sensitization of Glioma Cells to Fas-Dependent Apoptosis by Chemotherapy-Induced Oxidative Stress. <i>Cancer Research</i> , 2005, 65, 5248-5255.	0.9	52
87	Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. <i>Neuro-Oncology</i> , 2005, 7, 436-451.	1.2	269
88	The Scatter Factor/Hepatocyte Growth Factor: c-Met Pathway in Human Embryonal Central Nervous System Tumor Malignancy. <i>Cancer Research</i> , 2005, 65, 9355-9362.	0.9	103
89	Targeting the c-Met Pathway Potentiates Glioblastoma Responses to $\hat{3}$ -Radiation. <i>Clinical Cancer Research</i> , 2005, 11, 4479-4486.	7.0	117
90	Neuronal Pentraxin 1: A Novel Mediator of Hypoxic-Ischemic Injury in Neonatal Brain. <i>Journal of Neuroscience</i> , 2004, 24, 4187-4196.	3.6	44

#	ARTICLE	IF	CITATIONS
91	Regulation of c-Met-dependent gene expression by PTEN. <i>Oncogene</i> , 2004, 23, 9173-9182.	5.9	51
92	CD44-independent hepatocyte growth factor/c-Met autocrine loop promotes malignant peripheral nerve sheath tumor cell invasion in vitro. <i>Glia</i> , 2004, 45, 297-306.	4.9	36
93	Vascular Gene Expression in Nonneoplastic and Malignant Brain. <i>American Journal of Pathology</i> , 2004, 165, 601-608.	3.8	168
94	Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells. <i>Cancer Research</i> , 2003, 63, 2990-6.	0.9	55
95	Reduction of stromal fibroblast-induced mammary tumor growth, by retroviral ribozyme transgenes to hepatocyte growth factor/scatter factor and its receptor, c-MET. <i>Clinical Cancer Research</i> , 2003, 9, 4274-81.	7.0	38
96	Scatter Factor/Hepatocyte Growth Factor Stimulation of Glioblastoma Cell Cycle Progression through G 1 Is c-Myc Dependent and Independent of p27 Suppression, Cdk2 Activation, or E2F1-Dependent Transcription. <i>Molecular and Cellular Biology</i> , 2002, 22, 2703-2715.	2.3	37
97	Primary brain tumours in adults. , 2002, , 1431-1447.		3
98	Neuroprotection by scatter factor/hepatocyte growth factor and FGF-1 in cerebellar granule neurons is phosphatidylinositol 3-kinase/Akt-dependent and MAPK/CREB-independent. <i>Journal of Neurochemistry</i> , 2002, 81, 365-378.	3.9	62
99	Neuroprotection by scatter factor/hepatocyte growth factor and FGF-1 in cerebellar granule neurons is phosphatidylinositol 3-kinase/Akt-dependent and MAPK/CREB-independent. <i>Journal of Neurochemistry</i> , 2002, 81, 901-901.	3.9	0
100	Microarray Analysis of Differential Gene Expression in Lead-Exposed Astrocytes. <i>Toxicology and Applied Pharmacology</i> , 2001, 176, 34-53.	2.8	53
101	Hepatocyte Growth Factor/Scatter Factor Blocks the Mitochondrial Pathway of Apoptosis Signaling in Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2001, 276, 47257-47265.	3.4	41
102	Induction of Vascular Endothelial Growth Factor in Human Astrocytes by Lead. <i>Journal of Biological Chemistry</i> , 2000, 275, 27874-27882.	3.4	73
103	Glioma Inhibition by HGF/NK2, an Antagonist of Scatter Factor/Hepatocyte Growth Factor. <i>Biochemical and Biophysical Research Communications</i> , 2000, 273, 287-293.	2.1	23
104	Scatter factor/hepatocyte growth factor gene transfer increases rat blood-brain glioma barrier permeability. <i>Brain Research</i> , 1999, 833, 173-180.	2.2	16
105	Alterations in blood-brain barrier glucose transport in SIV-infected macaques. <i>Journal of NeuroVirology</i> , 1999, 5, 695-702.	2.1	26
106	Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. <i>International Journal of Developmental Neuroscience</i> , 1999, 17, 517-530.	1.6	97
107	IL-10 gene transfer to intracranial 9L glioma: tumor inhibition and cooperation with IL-2. <i>Journal of Neuroimmunology</i> , 1998, 92, 50-59.	2.3	22
108	Scatter factor promotes motility of human glioma and neuromicrovascular endothelial cells. , 1998, 75, 19-28.		108

#	ARTICLE	IF	CITATIONS
109	Human FGF-1 gene delivery protects against quinolinate-induced striatal and hippocampal injury in neonatal rats. <i>European Journal of Neuroscience</i> , 1998, 10, 2490-2499.	2.6	31
110	Human FGF-1 gene delivery protects against quinolinate-induced striatal and hippocampal injury in neonatal rats. <i>European Journal of Neuroscience</i> , 1998, 10, 2490-2499.	2.6	1
111	Dexamethasone inhibits Glioma-induced Formation of Capillary like Structures in vitro and Angiogenesis in vivo. <i>Klinische Padiatrie</i> , 1997, 209, 275-277.	0.6	27
112	Scatter Factor/Hepatocyte Growth Factor Expression Enhances Human Glioblastoma Tumorigenicity and Growth. <i>Biochemical and Biophysical Research Communications</i> , 1997, 235, 743-747.	2.1	66
113	Endothelial cell-based cytokine gene delivery inhibits 9L glioma growth in vivo. <i>Brain Research</i> , 1996, 731, 161-170.	2.2	21
114	Scatter factor expression and regulation in human glial tumors. , 1996, 67, 248-255.		110
115	Modulation of Serine Proteinases and Metalloproteinases During Morphogenic Gialâ€Endothelial Interactions. <i>Journal of Neurochemistry</i> , 1996, 66, 1657-1664.	3.9	11
116	Regulation of in vitro glia-induced microvessel morphogenesis by urokinase. <i>Journal of Cellular Physiology</i> , 1994, 158, 317-324.	4.1	14
117	Dexamethasone reduces vascular density and plasminogen activator activity in 9L rat brain tumors. <i>Brain Research</i> , 1993, 604, 79-85.	2.2	62
118	Selective endothelial growth inhibition by tetracyclines that inhibit collagenase. <i>Biochemical and Biophysical Research Communications</i> , 1992, 188, 740-745.	2.1	63
119	Steroid Inhibition of Neural Micro vessel Morphogenesis In Vitro: Receptor Mediation and Astroglial Dependence. <i>Journal of Neurochemistry</i> , 1992, 58, 1023-1032.	3.9	39
120	Astroglial-Induced In Vitro Angiogenesis: Requirements for RNA and Protein Synthesis. <i>Journal of Neurochemistry</i> , 1991, 57, 1231-1239.	3.9	46
121	Astrocytes induce neural microvascular endothelial cells to form capillary-like structures in vitro. <i>Journal of Cellular Physiology</i> , 1990, 144, 204-215.	4.1	115
122	Contact formation by fibroblasts adhering to heparan sulfate-binding substrata (fibronectin or Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 22	2.6	58